The Hollow Stay: Why NDASA and MMJ BioPharma’s Challenge to Cannabis Rescheduling Falls Apart Under Federal Law

On May 16, 2024, the United States Drug Enforcement Administration published a notice of proposed rulemaking to reschedule cannabis from Schedule I to Schedule III of the Controlled Substances Act. The move, prompted by a Department of Health and Human Services recommendation following a comprehensive scientific and medical evaluation, would formally recognize cannabis’s accepted medical use and lower abuse potential relative to opioids, anabolic steroids, and other Schedule I and II substances. 21 USCS § 812 (2025). For an industry built on prohibition enforcement—drug-testing companies, abstinence-only treatment providers, and certain pharmaceutical interests—the prospect of rescheduling represents an existential threat to revenue streams sustained by decades of federal criminalization.

Enter the National Drug and Alcohol Screening Association (NDASA) and MMJ BioPharma, Inc. In September 2024, these parties petitioned the United States Court of Appeals for the District of Columbia Circuit to stay the DEA’s rescheduling order, arguing that implementation would cause them irreparable harm. Their central claims: that rescheduling would trigger “ballooning cannabis access,” undermine workplace drug-testing programs, and damage their business models. On their face, these assertions sound urgent. Under scrutiny, they collapse.

The Federal Stay Standard: A High Bar by Design

Federal courts do not grant stays lightly. A stay pending appeal is an extraordinary form of relief that disrupts the ordinary course of agency action and judicial proceedings. Nken v. Holder, 556 U.S. 418, 428 (2009) The party seeking a stay bears the burden of justifying that disruption through a rigorous four-factor analysis. Id. at 434.

Under the framework established by the Supreme Court in Nken v. Holder, a movant must demonstrate: (1) a strong likelihood of success on the merits; (2) that it will suffer irreparable injury absent a stay; (3) that the stay will not substantially injure other interested parties; and (4) that the public interest favors a stay. Id. at 434, Revel AC, Inc. v. IDEA Boardwalk LLC, 802 F.3d 558, 568 (2015) Courts have consistently identified the first two factors—likelihood of success and irreparable harm—as “the most critical.” Id. The movant must show not merely a “possibility” of harm but a likelihood of injury that “cannot be prevented or fully rectified” by a successful appeal. Id.

Critically, economic injury alone does not satisfy the irreparable harm requirement. A stay is not a mechanism to insulate businesses from regulatory change or market disruption. Where money damages can compensate the asserted injury, equity will not intervene. Id. at 572. This principle reflects a fundamental distinction in American law: courts exist to remedy concrete, individualized harms that cannot be addressed through ordinary legal processes, not to protect abstract business interests from the inevitable winners and losers created by regulatory evolution. Lujan v. Defenders of Wildlife, 504 U.S. 555, 562-63 (1992).

NDASA and MMJ’s Irreparable Harm Claim: A Study in Legal Insufficiency

NDASA and MMJ BioPharma’s stay motion rests on a straightforward economic proposition: if cannabis moves to Schedule III, demand for their services will decline, causing revenue loss. NDASA represents drug-testing laboratories and screening companies whose clients—primarily employers—rely on federal drug-free workplace policies tied to Schedule I status. MMJ BioPharma, despite its name, appears to operate a pharmaceutical interest threatened by increased competition from rescheduled cannabis products.

Their argument fails at the threshold. Loss of business revenue due to regulatory change is the paradigm of compensable economic harm. When a business loses revenue because regulations change, courts generally treat that as ordinary economic harm that can be measured and compensated with money damages—not as irreparable harm. Revel AC, Inc. v. IDEA Boardwalk LLC, 802 F.3d 558, 572. NDASA members may lose contracts; MMJ may face increased competition. These are marketplace consequences, not irreparable injuries. If the rescheduling order is ultimately set aside on appeal, petitioners can seek damages for lost revenue, lost contracts, or diminished market position through subsequent litigation. The availability of that remedy forecloses the extraordinary relief of a stay.

More fundamentally, petitioners have failed to establish Article III standing to challenge the rescheduling in the first instance. Gettman v. DEA, 290 F.3d 430, 434 (2002). The mere fact that the Controlled Substances Act permits “any interested party” to petition the DEA for rulemaking does not automatically confer judicial standing to challenge the agency’s decision in federal court. Id. at 433-34. Participation in agency proceedings alone is insufficient; petitioners must demonstrate a concrete, particularized injury traceable to the agency action and redressable by a favorable decision. Id., Lujan at 561-62. A generalized grievance about market disruption does not meet this standard.

Courts have repeatedly rejected the notion that economic actors harmed by regulatory change suffer irreparable injury. In Alabama Association of Realtors v. HHS, landlords facing an eviction moratorium established irreparable harm not through lost rent alone but through the deprivation of a fundamental property right—the right to exclude. Ala. Ass’n of Realtors v. HHS, 594 U.S. 758, 765 (2021). NDASA and MMJ assert no comparable deprivation. They claim only that their business models, built around Schedule I prohibition, will become less profitable under Schedule III regulation. That is not a constitutionally protected interest; it is a business risk.

The petitioners’ motion also ignores the sliding-scale nature of the stay analysis. Revel at 567-68. Even assuming economic harm could qualify as irreparable in some contexts, petitioners would need to present an exceptionally strong case on the merits to justify a stay. Id. at 568 (2015) They have not. The DEA’s rescheduling decision followed years of scientific review, a formal HHS recommendation, and compliance with the statutory criteria for Schedule III placement. 21 USCS § 811, 812. Cannabis has a currently accepted medical use in treatment in the United States—acknowledged by 3841 states with operational medical cannabis programs—and a potential for abuse less than Schedule I and II substances. 21 USCS § 812, Peridot Tree, Inc. v. City of Sacramento, 94 F.4th 916, 923 (2024) Challenging that factual and scientific determination on the merits is a steep climb. Americans for Safe Access v. DEA, 706 F.3d 438, 440-41 (2013).

The “Ballooning Cannabis Access” Myth: An Argument Unmoored from Reality

Perhaps the most striking feature of NDASA and MMJ’s stay motion is the claim that rescheduling cannabis to Schedule III will cause “ballooning cannabis access” and a corresponding surge in consumption. This assertion is implausible on its face and unsupported by evidence.

As of September 2024, recreational cannabis was legal in 24 states, the District of Columbia, and multiple U.S. territories, covering more than half the U.S. population. Peridot Tree at 923. Medical cannabis was legal in 38 states and the District of Columbia. Id. Today, 41 states have medical cannabis programs. The notion that rescheduling—a change in federal administrative classification—will meaningfully expand access ignores the reality that cannabis is already widely available through state-licensed dispensaries, delivery services, and retail outlets operating in open defiance of federal Schedule I status.

Rescheduling does not legalize recreational cannabis. It does not authorize new dispensaries. It does not override state law. What it does is reclassify cannabis for purposes of federal drug regulation, removing certain penalties under the Controlled Substances Act and aligning federal treatment with the scientific consensus that cannabis has accepted medical uses and lower abuse potential than substances like fentanyl, oxycodone, and methamphetamine. 21 USCS § 812, Gonzales v. Raich, 545 U.S. 1, 28 (2005).

The Controlled Substances Act’s regulatory structure makes clear that Schedule III substances remain tightly controlled. Id. Manufacture, distribution, and dispensing of Schedule III drugs require DEA registration, compliance with production quotas, security controls, recordkeeping obligations, and adherence to prescription requirements. Id., 21 USCS §§ 821-830. These are not trivial barriers. The rescheduling process does not eliminate federal oversight; it recalibrates it to reflect scientific reality.

Moreover, consumption patterns are driven by state-level legalization, not federal scheduling. States that have legalized recreational cannabis have seen stabilization—not explosion—of usage rates following initial increases tied to the transition from black markets to legal markets. Federal rescheduling, which leaves state prohibition regimes intact, will not alter this dynamic. A resident of Idaho, where cannabis remains fully illegal, will not suddenly gain legal access because the DEA moved cannabis from Schedule I to Schedule III. Conversely, a resident of Colorado, where recreational cannabis has been legal since 2012, will experience no change in access whatsoever.

The “ballooning access” argument is a rhetorical flourish designed to invoke fear rather than a factual prediction grounded in evidence. It is, in short, nonsense.

The Real Stakes: Preserving a Predatory Business Model

Strip away the legal formalism and the petitioners’ true interest comes into focus: NDASA and MMJ BioPharma are defending a business model built on cannabis prohibition. For workplace drug-testing companies, Schedule I status provides regulatory cover for zero-tolerance policies that generate demand for screening services. For pharmaceutical interests opposed to rescheduling, maintaining cannabis in Schedule I limits competition from a plant-based therapeutic that cannot be patented in the same manner as synthetic drugs.

This is not a public-interest lawsuit. It is a profit-protection effort dressed in the language of irreparable harm. The federal courts have no obligation to insulate these actors from the consequences of scientific progress and regulatory reform.

Regulatory changes create winners and losers. The Controlled Substances Act’s scheduling system is designed to adapt as scientific understanding evolves. 21 USCS § 811. The DEA’s authority to reschedule substances exists precisely to ensure that federal drug policy reflects current medical knowledge, not the entrenched interests of industries that profit from prohibition. Id.

Conclusion

NDASA and MMJ BioPharma’s motion for a stay pending appeal was a transparent attempt to preserve an outdated prohibition regime that serves their financial interests at the expense of sound drug policy. Their irreparable harm claim failed to meet the federal standard. Their “ballooning access” argument defied observable reality. And their standing to challenge the rescheduling in the first instance remains dubious.

The D.C. Circuit’s denial of the stay motion was legally correct and substantively unremarkable. What is remarkable is that these petitioners believed a court would halt a science-driven rescheduling process to protect their revenue streams.



Regulatory evolution is not a judicial emergency. It is how law catches up with reality. If your business model depends on the government keeping a medically useful plant in the same legal category as heroin, perhaps the problem isn’t the rescheduling order. Perhaps the problem is the business model. Deal with it.